Therapeutic potential of phytocannabinoids in depression and cognitive dysfunction: Evidence from preclinical models.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie May 1, 2026 Carla Fonseca, F. Gouveia, Soraia Silva et al.
Depression is a highly prevalent and incident mental illness. Current pharmacological therapies fail in approximately 30-40% of patients, highlighting the urgent need for novel agents with pleiotropic effects. This preclinical study aimed to identify new antidepressants and cognitive modulators among five phytocannabinoids: cannabichromene, cannabidiol, cannabidivarin, cannabigerol and...